AI
MACK

Analytic Investors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Analytic Investors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,005
Closed -$134K – 710
2015
Q3 		$134K Buy
+2,005
New +$164K ﹤0.01% 537

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Analytic Investors's MACK Position: Q4 2015 in Review

Analytic Investors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2015, closing a stake of 2,005 shares — an estimated $134K sold.

Analytic Investors first reported a position in MACK in Q3 2015 and held it in 1 quarter. The position peaked at $134K in Q3 2015. 139 funds tracked by Wall St. Rank hold MACK as of Q4 2015.

  • Analytic Investors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Analytic Investors sold 2,005 Merrimack Pharmaceuticals, Inc. shares in Q4 2015, an estimated $134K.
  • Analytic Investors first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2015 and held it in 1 quarter.
  • Analytic Investors's Merrimack Pharmaceuticals, Inc. position peaked at $134K in Q3 2015.
  • 139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2015.

Based on Analytic Investors's 13F filing for Q4 2015, filed 12 Feb 2016.